Bibliography
- Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63(12):1762-84
- Merck & Co., Inc. Sahphris (asenapine) sublingual tablets. Prescribing information, revised March 2013. Available from: http://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdf [Accessed 19 January 2014]
- Citrome L. Asenapine review, part II: Clinical efficacy, safety and tolerability. Expert Opin Drug Saf 2014;13(6):803-30
- US Food and Drug Administration. Asenapine Drug Approval Package. October 2, 2009, updated December 18, 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000TOC.cfm [Accessed 20 January 2014]
- US Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. July 30, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf [Accessed 26 January 2014]
- Schering-Plough Research Institute. Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package). July 30, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf [Accessed 26 January 2014]
- Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10(12):1917-28
- Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 2013;27(11):879-911
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
- De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 2012;26(9):733-59
- Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(10 Suppl 11):6-14
- Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2012;25(2):96-102
- Freedman R. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 2014;65:245-61
- Stevenson R, Wolde HT. Update 4 – Akzo, Pfizer Scrap Asenapine Joint Development. November 28, 2006. Available from: http://www.reuters.com/article/companyNewsAndPR/idUSL286087420061128 [Accessed 19 January 2014]
- Costall B, Domeney AM, Kelly ME, et al. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35(3):607-15
- Forest Laboratories, Inc. Forest to acquire U.S. marketing rights to Saphris (asenapine) from Merck. Press release. December 2, 2013. Available from: http://news.frx.com/press-release/business-development-news/forest-acquire-us-marketing-rights-saphris-asenapine-merck [Accessed 19 January 2014]
- Lundbeck. Lundbeck and Merck sign exclusive commercialisation agreement for Sycrest (asenapine) sublingual tablets in all markets outside of the United States, China and Japan. Press release. October 12, 2010. Available from: http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608583 [Accessed 19 January 2014]
- Lundbeck. Sycrest 5mg and 10mg sublingual tablets. Summary of Product Characteristics. Last updated April 18, 2013. Available from: http://www.medicines.org.uk/emc/medicine/25632/SPC/Sycrest+5mg+and+10mg+sublingual+tablets/ [Accessed 2 February 2014]
- Funke CW, Hindriks H, Sam AP. Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 1990;40(5):536-9
- Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23(1):65-73
- Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience 2007;149(1):192-202
- Frånberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196(3):417-29
- Tarazi FI, Neill JC. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov 2013;8(1):93-103
- Bartlett JA, van der Voort Maarschalk K. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS Pharm Sci Tech 2012;13(4):1110-15
- Gerrits M, de Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos 2010;31(5-6):351-7
- van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos 2011;39(4):580-90
- Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet 2011;50(7):471-81
- Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry 2012;27(5):472-82
- Gerrits MG, de Greef R, Dogterom P, Peeters PA. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol 2012;52(5):757-65
- Andrée B, Halldin C, Vrijmoed-de Vries M, Farde L. Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology (Berl) 1997;131(4):339-45
- Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 2011;31(4):497-502
- Sun X, Hamer R, McEvoy J. Once daily dosing improves asenapine effectiveness, patient acceptance and adherence as compared to twice daily dosing. Poster presentation II-87. NCDEU; May 28-31, 2013; Hollywood, Florida
- Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand 2014. [Epub ahead of print]
- Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
- Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68(10):1492-500
- Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30(2):106-15
- Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry 2011;72(3):349-55
- McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11(7):673-86
- McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122(1-2):27-38
- Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32(1):46-55
- de Boer T, Meulman E, Meijering H, et al. Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. Biomed Chromatogr 2012;26(2):156-65